Literature DB >> 24916848

Hypomyelinating leukodystrophies: translational research progress and prospects.

Petra J W Pouwels1, Adeline Vanderver, Genevieve Bernard, Nicole I Wolf, Steffi F Dreha-Kulczewksi, Sean C L Deoni, Enrico Bertini, Alfried Kohlschütter, William Richardson, Charles Ffrench-Constant, Wolfgang Köhler, David Rowitch, A James Barkovich.   

Abstract

Hypomyelinating leukodystrophies represent a genetically heterogeneous but clinically overlapping group of heritable disorders. Current management approaches in the care of the patient with a hypomyelinating leukodystrophy include use of serial magnetic resonance imaging (MRI) to establish and monitor hypomyelination, molecular diagnostics to determine a specific etiology, and equally importantly, careful attention to neurologic complications over time. Emerging research in oligodendrocyte biology and neuroradiology with bedside applications may result in the possibility of clinical trials in the near term, yet there are significant gaps in knowledge in disease classification, characterization, and outcome measures in this group of disorders. Here we review the biological background of myelination, the clinical and genetic variability in hypomyelinating leukodystrophies, and the insights that can be obtained from current MRI techniques. In addition, we discuss ongoing research approaches to define potential outcome markers for future clinical trials.
© 2014 American Neurological Association.

Entities:  

Mesh:

Year:  2014        PMID: 24916848     DOI: 10.1002/ana.24194

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  53 in total

1.  A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy.

Authors:  Cas Simons; David Dyment; Stephen J Bent; Joanna Crawford; Marc D'Hooghe; Alfried Kohlschütter; Sunita Venkateswaran; Guy Helman; Bwee-Tien Poll-The; Christine C Makowski; Yoko Ito; Kristin Kernohan; Taila Hartley; Quinten Waisfisz; Ryan J Taft; Marjo S van der Knaap; Nicole I Wolf
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

2.  Myelin-associated glycoprotein gene mutation causes Pelizaeus-Merzbacher disease-like disorder.

Authors:  Alexander Lossos; Nimrod Elazar; Israela Lerer; Ora Schueler-Furman; Yakov Fellig; Benjamin Glick; Bat-El Zimmerman; Haim Azulay; Shlomo Dotan; Sharon Goldberg; John M Gomori; Penina Ponger; J P Newman; Hodaifah Marreed; Andreas J Steck; Nicole Schaeren-Wiemers; Nofar Mor; Michal Harel; Tamar Geiger; Yael Eshed-Eisenbach; Vardiella Meiner; Elior Peles
Journal:  Brain       Date:  2015-07-15       Impact factor: 13.501

3.  Consensus paper: radiological biomarkers of cerebellar diseases.

Authors:  Leonardo Baldarçara; Stuart Currie; M Hadjivassiliou; Nigel Hoggard; Allison Jack; Andrea P Jackowski; Mario Mascalchi; Cecilia Parazzini; Kathrin Reetz; Andrea Righini; Jörg B Schulz; Alessandra Vella; Sara Jane Webb; Christophe Habas
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

4.  Pathogenic variants in AIMP1 cause pontocerebellar hypoplasia.

Authors:  Andrea Accogli; Laura Russell; Guillaume Sébire; Jean-Baptiste Rivière; Judith St-Onge; Nassima Addour-Boudrahem; Alexandre Dionne Laporte; Guy A Rouleau; Christine Saint-Martin; Myriam Srour
Journal:  Neurogenetics       Date:  2019-03-28       Impact factor: 2.660

Review 5.  Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease.

Authors:  M Joana Osorio; David H Rowitch; Paul Tesar; Marius Wernig; Martha S Windrem; Steven A Goldman
Journal:  Stem Cells       Date:  2016-11-23       Impact factor: 6.277

6.  Oculodentodigital Dysplasia: A Hypomyelinating Leukodystrophy with a Characteristic MRI Pattern of Brain Stem Involvement.

Authors:  I Harting; S Karch; U Moog; A Seitz; P J W Pouwels; N I Wolf
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-02       Impact factor: 3.825

7.  Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model.

Authors:  Elena Georgiou; Kyriaki Sidiropoulou; Jan Richter; Christos Papaneophytou; Irene Sargiannidou; Alexia Kagiava; Georg von Jonquieres; Christina Christodoulou; Matthias Klugmann; Kleopas A Kleopa
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

Review 8.  Glial progenitor cell-based treatment of the childhood leukodystrophies.

Authors:  M Joana Osorio; Steven A Goldman
Journal:  Exp Neurol       Date:  2016-05-08       Impact factor: 5.330

Review 9.  Emerging treatments for pediatric leukodystrophies.

Authors:  Guy Helman; Keith Van Haren; Maria L Escolar; Adeline Vanderver
Journal:  Pediatr Clin North Am       Date:  2015-04-08       Impact factor: 3.278

10.  Genetic heterogeneity in 26 infants with a hypomyelinating leukodystrophy.

Authors:  Natsuko Arai-Ichinoi; Mitsugu Uematsu; Ryo Sato; Tasuku Suzuki; Hiroki Kudo; Atsuo Kikuchi; Naomi Hino-Fukuyo; Mitsuyo Matsumoto; Kazuhiko Igarashi; Kazuhiro Haginoya; Shigeo Kure
Journal:  Hum Genet       Date:  2015-11-23       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.